FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients
Executive Summary
FDA's Office of Postmarketing Drug Risk Assessment is "discouraging" applications that would create a new brand name for an existing active ingredient.
You may also be interested in...
Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension
Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra
Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension
Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra
Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand
Lilly is asking FDA to accept Yentreve as the trade name for duloxetine for the treatment of stress urinary incontinence